A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection.

Lage, Daniela PagliaraRibeiro, Patrícia Aparecida FernandesDias, Daniel SilvaMendonça, Débora Vasconcelos CostaRamos, Fernanda FonsecaCarvalho, Lívia MendesOliveira, Daysiane deSteiner, Bethina TrevisolMartins, Vivian TamiettiMelo, Luísa Helena Perin deMachado, Amanda SanchezSantos, Thaís Teodoro de OliveiraTavares, Grasiele de Sousa VieiraHumbert, Maria VictoriaCoelho, Eduardo Antônio FerrazChristodoulides, Myron2021-09-302021-09-302020LAGE, D. P. et al. A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection. Vaccines, v. 5, artigo 75, ago. 2020. Disponível em: <https://www.nature.com/articles/s41541-020-00224-0>. Acesso em: 10 jun. 2021.2059-0105http://www.repositorio.ufop.br/jspui/handle/123456789/13826Leishmaniases are neglected diseases caused by infection with Leishmania parasites and there are currently no prophylactic vaccines. In this study, we designed in silico a synthetic recombinant vaccine against visceral leishmaniasis (VL) called ChimeraT, which contains specific T-cell epitopes from Leishmania Prohibitin, Eukaryotic Initiation Factor 5a and the hypothetical LiHyp1 and LiHyp2 proteins. Subcutaneous delivery of ChimeraT plus saponin stimulated a Th1 cell-mediated immune response and protected mice against L. infantum infection, significantly reducing the parasite load in distinct organs. ChimeraT/saponin vaccine stimulated significantly higher levels of IFN-γ, IL-12, and GM-CSF cytokines by both murine CD4+ and CD8+ T cells, with correspondingly low levels of IL-4 and IL-10. Induced antibodies were predominantly IgG2a isotype and homologous antigen-stimulated spleen cells produced significant nitrite as a proxy for nitric oxide. ChimeraT also induced lymphoproliferative responses in peripheral blood mononuclear cells from VL patients after treatment and healthy subjects, as well as higher IFN-γ and lower IL-10 secretion into cell supernatants. Thus, ChimeraT associated with a Th1 adjuvant could be considered as a potential vaccine candidate to protect against human disease.en-USabertoA candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection.Artigo publicado em periodicoThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Fonte: o PDF do artigo.https://doi.org/10.1038/s41541-020-00224-0